Ipamorelin is a selective ghrelin receptor agonist that triggers pulsatile growth hormone release without strongly affecting cortisol or prolactin.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) that extends the half-life of endogenous GHRH signaling.
When combined, the two are studied as a complementary blend: CJC-1295 raises baseline GHRH tone while Ipamorelin produces sharper, more physiological pulses.
For research-use details and recommended laboratory dosing, see the CJC/IPA product page.